Quotes 5-day view Delayed Nasdaq
01/23/2023
01/24/2023
01/25/2023
01/26/2023
01/27/2023
Date
53.98(c)
54.23(c)
53.25(c)
53.84(c)
52.71(c)
Last
602 118
988 030
512 614
302 760
1 488 208
Volume
-0.46%
+0.46%
-1.81%
+1.11%
-2.10%
Change
Estimated financial data (e) (USD)
Sales 2022
135 M
-
-
Net income 2022
-401 M
-
-
Net cash position 2022
349 M
-
-
P/E ratio 2022
-40,4x
Yield 2022
-
Sales 2023
182 M
-
-
Net income 2023
-388 M
-
-
Net cash position 2023
340 M
-
-
P/E ratio 2023
-38,8x
Yield 2023
-
Capitalization
8 824 M
8 824 M
-
EV / Sales 2022
62,6x
EV / Sales 2023
46,5x
Nbr of Employees
1 071
Free-Float
5,97%
Legend Biotech Corporation is a global, clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly...
Ratings of Legend Biotech Corporation
All news about LEGEND BIOTECH CORPORATION
News in other languages on LEGEND BIOTECH CORPORATION
Analyst Recommendations on LEGEND BIOTECH CORPORATION
ETFs positioned on LEGEND BIOTECH CORPORATION ETFs and Trackers with Trackinsight
Chart LEGEND BIOTECH CORPORATION
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends LEGEND BIOTECH CORPORATION
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
12
Last Close Price
52,71 $
Average target price
72,56 $
Spread / Average Target
37,7%
Please enable JavaScript in your browser's settings to use dynamic charts.